购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Epigenetic Reader Domain
    (2)
  • Others
    (3)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 35日内发货
    (1)
  • 6-8周
    (1)
  • 10-14周
    (1)
筛选
搜索结果
TargetMol产品目录中 "

brd4 inhibitor-10

"的结果
  • 抑制剂&激动剂
    6
    TargetMol | Inhibitors_Agonists
  • BRD4 Inhibitor-10
    T147761660117-38-3
    BRD4 Inhibitor-10 是一种BRD4-BD1抑制剂,IC50为 8 nM。
    • ¥ 297
    现货
    规格
    数量
    TargetMol | Inhibitor Sale
  • MS436
    T18541395084-25-9
    MS436 是溴结构域抑制剂,作用于 BRD4 BrD1的Ki 为 30 到 50 nM 之间,比作用于 BrD2 选择性高 10 倍。
    • ¥ 266
    现货
    规格
    数量
    TargetMol | Inhibitor Sale
  • BET-IN-20
    T858461300735-76-5
    BET-IN-20 (compound 10) 作为 BRD4 BD1 的抑制剂 (IC50=1.9 nM),显示出显著的抗癌活性。该化合物能够促使急性髓系白血病 (AML) 细胞发生凋亡,并在 G0 G1 期阻止细胞周期的进程。此外,BET-IN-20 直接抑制 c-Myc 和 CDK6,同时促进 PARP 的裂解。
    • 待询
    10-14周
    规格
    数量
  • CAY17c
    T383812414373-11-6
    CAY17c is an inhibitor of bromodomain-containing protein 4 (BRD4; IC50= 0.71 μM), as well as class I histone deacetylases (HDACs; IC50s = 0.046, 0.058, 0.075, and 0.167 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.073 and 0.923 μM for HDAC6 and HDAC10, respectively).1It is selective for these enzymes over BRD2, -3, and -T (IC50s = >20 μM for all), as well as over HDAC4, -5, -7, -9, and -11 (IC50s = >10 μM for all). CAY17c inhibits the proliferation of HCT116, SW620, and DLD-1 colorectal cancer cells (IC50s = 0.45, 1.78, and 2.11 μM, respectively), as well as induces apoptosis and autophagy in HCT116 cells. It reduces tumor growth in an HCT116 mouse xenograft model when administered at doses of 15 and 30 mg/kg. 1.Pan, Z., Li, X., Wang, Y., et al.Discovery of thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4/histone deacetylase dual inhibitors induce autophagic cell death in colorectal carcinoma cellsJ. Med. Chem.63(7)3678-3700(2020)
    • 待估
    35日内发货
    规格
    数量
  • tw9
    TW9
    T36103
    TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μM) and for HDAC1 over HDAC2 (IC50= 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells. 1.Zhang, X., Zegar, T., Weiser, T., et al.Characterization of a dual BET HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaInt. J. Cancer147(10)2847-2861(2020)
    • ¥ 852
    期货
    规格
    数量
  • bromodomain inhibitor-10
    T613871870849-58-3
    Bromodomain inhibitor-10 (compound 128) is a highly potent inhibitor of bromodomain activity. It exhibits strong binding affinity with K d values of 15.0 nM and 2500 nM for BRD4-1 and BRD4-2, respectively. Furthermore, Bromodomain inhibitor-10 effectively inhibits the production of IL12p40 [1].
    • ¥ 10600
    6-8周
    规格
    数量